Literature DB >> 22785182

Papillary thyroid carcinoma involving cervical neck lymph nodes: correlations with lymphangiogenesis and ultrasound features.

Yoonjung Choi1, Kyung Joo Park, Seungho Ryu, Dong-Hoon Kim, Jisup Yun, Doo Kyoung Kang, Mison Chun.   

Abstract

Stratification of risk factors for cervical lymph node metastasis (LNM) in thyroid papillary carcinoma is important for providing standards for post-operative adjuvant radio-iodine therapy and for patient prognosis. We investigated pathological factors based on the lymphatic vessel system and radiological features associated with tumor with cervical neck LNM. Among patients who had undergone thyroidectomy confirmed to be papillary thyroid carcinoma, we selected 126 age-sex matched paired patients without cervical LNM (group 1) and with LNM (group 2) to evaluate risk factors. Pathological factors evaluated were size, multiplicity, and extra thyroid extension state, based on the pathological reports using stored data. The lymphatic vessel density (LVD) of each tumor was evaluated by staining for VEGFR-3 and D2-40 and correlated with cervical LNM state. Malignant ultrasound features were evaluated to compare the differences between these two groups. Larger tumor size, multiplicity, extrathyroid extension were more common in group 2 (p<0.05). The median percentage of VEGFR-3 for group 1 was 20 (range 0-30) and D2-40 was 13 (range 7-23) while for group 2, VEGFR-3 was 80 (70-90) and D2-40 was 78 (54-114). LVD measured by intratumoral D2-40 staining was 20.6% and 79.4% for group 1 and group 2, respectively. Intra-tumoral lymphatics measured by D2-40 stain had a strong correlation with cervical LNM (Odds 1.230, CI 1.01.-1.499 p value 0.040). Ultrasound (US) features had no significant differences between the two groups although calcifications tended to be higher in group 2 (84% vs. 76% p=0.264). Lymphatic vessel density and nodule echogenicity were not associated with LNM. Intratumoral lymphangiogenesis was most strongly associated with LNM and thus, could be a useful predictive marker for cervical LNM.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22785182     DOI: 10.1507/endocrj.ej12-0178

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  6 in total

1.  BRAFV600E Mutation: Has It a Role in Cervical Lymph Node Metastasis of Papillary Thyroid Cancer?

Authors:  Neslihan Kurtulmus; Burak Ertas; Yesim Saglican; Hakan Kaya; Umit Ince; Mete Duren
Journal:  Eur Thyroid J       Date:  2016-08-20

2.  Predictive factors for lymph node metastasis in solitary papillary thyroid carcinomas: a retrospective study.

Authors:  Fábio Muradás Girardi; Marinez Bizarro Barra; Cláudio Galleano Zettler
Journal:  Pathol Oncol Res       Date:  2014-05-02       Impact factor: 3.201

3.  Can increased tumoral vascularity be a quantitative predicting factor of lymph node metastasis in papillary thyroid microcarcinoma?

Authors:  Hyun Joo Shin; Eun-Kyung Kim; Hee Jung Moon; Jung Hyun Yoon; Kyung Hwa Han; Jin Young Kwak
Journal:  Endocrine       Date:  2013-12-24       Impact factor: 3.633

4.  Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma?

Authors:  Wenliang Ma; Jun Yang; Ning Liu; Xiaohong Pu; Feng Qu; Linfeng Xu; Xiaozhi Zhao; Xiaogong Li; Gutian Zhang; Hongqian Guo; Dongmei Li; Weidong Gan
Journal:  BMC Cancer       Date:  2020-12-02       Impact factor: 4.430

5.  Steroid receptor coactivator-1 interacts with NF-κB to increase VEGFC levels in human thyroid cancer.

Authors:  Bo Gao; Lingji Guo; Donglin Luo; Yan Jiang; Jianjie Zhao; Chengyi Mao; Yan Xu
Journal:  Biosci Rep       Date:  2018-06-12       Impact factor: 3.840

6.  Detection and prognostic value of intratumoral and peritumoral lymphangiogenesis in colorectal cancer.

Authors:  Yanbin Zhang; Yue Liu; Danhua Shen; Hui Zhang; Hongyan Huang; Sha Li; Jun Ren
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.